Eliquis Superiority Claim May Be At Stake In “Complete Response” Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA could have concerns about the reported data from the ARISTOTLE trial, either from the bleeding comparisons or the dosing in the warfarin control arm. Missing data is another possible issue, as in the recent “complete response” letter for J&J/Bayer’s Xarelto.
You may also be interested in...
On Heels Of U.S. Approval, BMS, Pfizer Launch Eliquis Ahead Of Pradaxa In China
Under a global collaboration, Bristol-Myers Squibb will co-commercialize Eliquis with Pfizer, but it must contend with Boehringer’s Pradaxa, which has a wider label in China.
On Heels Of U.S. Approval, BMS, Pfizer Launch Eliquis Ahead Of Pradaxa In China
Under a global collaboration, Bristol-Myers Squibb will co-commercialize Eliquis with Pfizer, but it must contend with Boehringer’s Pradaxa, which has a wider label in China.
A More Disciplined Teva Gets Lukewarm Reception From Street
More organizational and strategic discipline, far greater selectivity in R&D and business development, and emphasis on profitable, not top-line, growth are at the core of the strategy put forth by Teva’s new management on Dec. 11. The reboot makes sense, given the company’s relentless focus on M&A over the past decade and its maturing generics businesses, so why are investors balking?